RWM
TNYA icon

Rialto Wealth Management’s Tenaya Therapeutics TNYA Stock Holding History

Rialto Wealth Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-833
Closed -$475 – 1762
2025
Q1 		$475 Buy
+833
New +$822 ﹤0.01% 904

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Rialto Wealth Management's TNYA Position: Q2 2025 in Review

Rialto Wealth Management sold out of Tenaya Therapeutics (TNYA) in Q2 2025, closing a stake of 833 shares — an estimated $475 sold.

Rialto Wealth Management first reported a position in TNYA in Q1 2025 and held it in 1 quarter. The position peaked at $475 in Q1 2025. 89 funds tracked by Wall St. Rank hold TNYA as of Q2 2025.

  • Rialto Wealth Management reported no remaining Tenaya Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 833 Tenaya Therapeutics shares in Q2 2025, an estimated $475.
  • Rialto Wealth Management first reported a position in Tenaya Therapeutics in Q1 2025 and held it in 1 quarter.
  • Rialto Wealth Management's Tenaya Therapeutics position peaked at $475 in Q1 2025.
  • 89 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2025.

Based on Rialto Wealth Management's 13F filing for Q2 2025, filed 6 Aug 2025.